Safety and efficacy of C. muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Safety and efficacy of C. muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG ; volume:9 ; number:1 ; day:10 ; month:6 ; year:2024 ; pages:1-10 ; date:12.2024
npj vaccines ; 9, Heft 1 (10.6.2024), 1-10, 12.2024
- Urheber
-
Slepenkin, Anatoli
Pal, Sukumar
Rasley, Amy
Coleman, Matthew A.
Maza, Luis M. de la
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41541-024-00880-6
- URN
-
urn:nbn:de:101:1-2408162153093.147856409422
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Slepenkin, Anatoli
- Pal, Sukumar
- Rasley, Amy
- Coleman, Matthew A.
- Maza, Luis M. de la
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mastoparan-7 adjuvanted COBRA H1 and H3 hemagglutinin influenza vaccines
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
II.1 Cpg 330, Cpg 338 und Cpg 389
Immunogenicity of adjuvanted versus high-dose inactivated influenza vaccines in older adults: a randomized clinical trial
Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design
Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach
III.1 Cpg 321 und Cpg 336
Mastoparan-7 adjuvanted COBRA H1 and H3 hemagglutinin influenza vaccines
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
II.1 Cpg 330, Cpg 338 und Cpg 389
Immunogenicity of adjuvanted versus high-dose inactivated influenza vaccines in older adults: a randomized clinical trial
Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design
Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach
III.1 Cpg 321 und Cpg 336
Mastoparan-7 adjuvanted COBRA H1 and H3 hemagglutinin influenza vaccines
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
II.1 Cpg 330, Cpg 338 und Cpg 389
Immunogenicity of adjuvanted versus high-dose inactivated influenza vaccines in older adults: a randomized clinical trial
Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design
Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach